Chemexpress(SH:688131) Xin Lang Cai Jing·2025-10-10 01:23Core Insights - On October 9, Haoyuan Pharmaceutical's stock rose by 3.49%, with a trading volume of 508 million yuan [1] - The company reported a financing buy-in of 70.22 million yuan and a net financing buy-in of 3.93 million yuan on the same day [1] - As of October 9, the total balance of margin trading for Haoyuan Pharmaceutical was 416 million yuan, indicating a high level of trading activity [1] Financing Summary - On October 9, Haoyuan Pharmaceutical had a financing buy-in of 70.22 million yuan, with a current financing balance of 414 million yuan, representing 2.29% of its market capitalization [1] - The financing balance is above the 90th percentile of the past year, indicating a high level of investor interest [1] Short Selling Summary - On October 9, Haoyuan Pharmaceutical repaid 4,660 shares in short selling and sold 3,000 shares, amounting to 256,400 yuan at the closing price [1] - The remaining short selling volume was 15,000 shares, with a short selling balance of 1.28 million yuan, which is above the 70th percentile of the past year [1] Company Overview - Haoyuan Pharmaceutical, established on September 30, 2006, is located in Shanghai and specializes in the discovery of small molecule drugs, including the development of molecular building blocks and tool compounds [2] - The company's main business revenue composition includes 68.97% from molecular building blocks, tool compounds, and biochemical reagents, with product sales contributing 63.42% [2] - As of September 19, the number of shareholders increased by 17.93% to 12,800, with an average of 16,527 circulating shares per person, a decrease of 12.82% [2] Financial Performance - For the first half of 2025, Haoyuan Pharmaceutical achieved a revenue of 1.311 billion yuan, representing a year-on-year growth of 24.20% [2] - The net profit attributable to shareholders was 152 million yuan, showing a significant year-on-year increase of 115.55% [2] Dividend Information - Since its A-share listing, Haoyuan Pharmaceutical has distributed a total of 143 million yuan in dividends, with 103 million yuan distributed over the past three years [3] Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder, holding 6.2611 million shares, an increase of 329,200 shares from the previous period [3] - The fund "China Europe Medical Health Mixed A" ranked fifth among circulating shareholders, holding 6.1185 million shares, a decrease of 2.7776 million shares from the previous period [3]